onyx shocked people with the new myeloma drug. it was in the numbers. onyx's new drug wasn't.e be abandoned? the credibility was damaged here. at the same time they reiterated estimates, talked about earning $8 to $9 in 2018 per share. i think celgene deserves some benefit of the doubt when they will follow up the uh approval when more data is available. they can be terrific speculations which is why i come to you. a country with serious entries in treating kidney, liver and now blood cancers. it makes onyx still a juicy takeover target. yes, celgene reminds us when a company dependent dpends on one drug the stock can be more dicey than you like. even as the $3.2 million dollar drug is the envy of many. it's imperative they show growth away from it while making the claim the drug is superior to anything onyx has to offer in the blood cancer category. i hope it can do so. i want to be a buyer but i'm chasing. a chasing buyer of that. you can be certain that's the case. i believe in celgene, but this was a stunner. stay with cramer. [ male announcer ] trophies and awards lift yo

it makes onyx still a juicy takeover target.elgene reminds us when a company dependent depends on one drug the stock can be more dicey than you like. even as the $3.2 million dollar drug is the envy of many. it's imperative they show growth away from it while making the claim the drug is superior to anything onyx has to offer in the blood cancer category. i hope it can do so. i want to be a buyer but i'm chasing bier. a chasing buyer of that. you can be certain that's the case. i believe in celgene, but this was a stunner. stay with cramer. how much coffee are you fellows going to need today? three...four cups? [dumbfounded] well, we... doesn't last long does it? listen. 5-hour energy lasts a whole lot of hours. so you can get a lot done without refills. it's packed with b-vitamins and nutrients to make it last. so don't just stand there holding your lattes, boys. make your move. we'll take the 5-hour energy. smart move. 5-hour energy. hours and hours of energy. with thirst-quenching fresh brewed fuze iced tea. fresh brewed for

it makes onyx still a juicy takeover target.n a company dependent depends on one drug the stock can be more dicey than you like. even as the $3.2 million dollar drug is the envy of many. it's imperative they show growth away from it while making the claim the drug is superior to anything onyx has to offer in the blood cancer category. i hope it can do so. i want to be a buyer but i'm chasing bier. a chasing buyer of that. you can be certain that's the case. i believe in celgene, but this was a stunner. stay with cramer. ♪music plays t summer in new york state has something different for everyone to love. discover what you love. visit ilovenewyork.com to plan your summer trip now. and then treats day after day... who gets heartburn well, shoot, that's like checking on your burgers after they're burnt! [ male announcer ] treat your frequent heartburn by blocking the acid with prilosec otc. and don't get heartburn in the first place! [ male announcer ] one pill a day. 24 hours. zero heartburn. [ engine turns over ] [ male announcer

a positive one on onyx's blood cancer drug. for bone cancerment blood cancer.ok at celgene as a number one maker in this space. the final fda decision expected by not on but by july 27th. >> what does nat gas and ercana in common? >> they're both found in canada. >> and moose. >> that's -- >> they move about sharely. shares down 8%. good news/bad news. people concerned about profit because they plan to invest another $600 million to drill. they'll have about 350 oil and gas wells next year. production up 11% and spending more to drill more. going to impact near-term product. >> spend money to make money. under armour with a downgrade of ubs. i guess not happy with the new sneaker, huh? >> down 5.8%, right? ubs concerned that this warm weather not just today but from may and april is pulling sales forward. i don't need a t-shirt last week. i bought it in march. keep in mind this stock is still up about 40% year to date. merrill lynch with a positive note on the stock. one of the major recommendation lists. a firm knocking it. a good year for under armour. >> not

onyx pharmaceutical. 37% jump it looks like. >> onyx is a reminder of why people should not give up onquities. why is this so huge? we knew they had an anti- -- they had kidney cancer. we knew they had liver cancer. those are dreaded, horrible diseases. now they have something for multip multiple myeloma people didn't know about. the birth of a major pharma from a -- >> there's a big short position here. i would think that also is helping that gain right there. >> yes. this is a bit like alexon. you have chronicled the smaller companies that get bids. this isn't that small anywhere. >> no. >> this is how big pharma grows. bear has their partners. this company is worth a fortune. they're withdrawing their european -- >> talk about a company that has grown enormously. >> bob u fwrks an, ceo, i'm not ruling him out. he did reiterate guidance. everyone wants to give up on cell gene. onyx may be the key to today's market. >> i love when you say that. >> a throw back to -- >> the 1980s. the opening bell just 3 1/2 minutes away. get ready for another big day of trading and a lot more "squawk

onyx pharmaceuticals shot up 43% after the f.d.a. advisory panel supported its treatment which goes for full f.d.a. okay in the months ahead. ligand jumped more than 13%, as it would get a portion of any revenue if the drug makes it to market. all five of the most actively traded exchange traded funds were lower, by at least 2%. the biggest drop was the emerging market fund, down 3.7%. and that's tonight's "market focus." >> susie: despite today's worries about a slowdown in the world's global growth engines. tonight's commtator ys the u.s. still has a lot going for it. here's eric schurenberg, editor- in-chief of inc. magazine. >> a venture capitalist, bruce gibney, recently stopped at inc. on his return from beijing. actually, inc. was his second stop in the u.s., the first was the city of troy, new york. beijing, troy. what gibney said, to my surprise, was that he'd take troy any day. now, i went to high school near troy, and the place has seen better days. but gibney found an innovative manufacturer there he thought was worth an

visit ilovenewyork.com to plan your summer trip now. >>> onyx pharmaceuticals is our stock of the dayblood cancer drug. our guest host this morning has been ed lazear, former chairman of the president's council of economic advisers. to summarize some of the stuff you said already in the last two hours, ed, is that it's not 50/50 for a recession in 2013. but you have certainly gotten more wary of that possibility. would you say 30/70? something like that? >> yeah. >> much higher than we thought. >> definitely higher. >> it implies less than 2% growth. >> things are worse than last time i was on. >> there are some things to be optimistic about? >> yeah. in terms of long-run prospects for this country there are plenty of things we can think of on the policy side and in terms of the kind of technology and human capital we have that are really strong things for the united states. think some of the things, by the way, we should be working on, we should be bringing in more high quality human capital that's complementary to what we're doing rather than substitutable for what we're doing. if y

onyx pharmaceuticals, shares up 37% after getting favorable recommendations. >> summer starts and nowack to some cooler temperatures around the bay area with low clouds and fog surging onto the bay area. clouds and even some drizzle out towards the coast line. members will stay well down across the board as low clouds and fog make their way inside the bay. low pressure is dropping out of the gulf of alaska and that will bring more drizzle. 73 in san jose, 58 and cool and breezy in the bay area. a couple of lingering clouds, 66 in oakland, 62 in san francisco. the next few days temperature's dropped through the weekend and it looks like we will slowly start to warm things up monday and tuesday. >> we have been following a hot spot, and earlier hot spot, along the peninsula. they just reopened all lanes of southbound interstate 1 01. it was really starting to stacked up and we're still seeing some brake lights just south of san francisco airport. no. around 101 at alum rock avenue, there is still one lane block. i have shown you a live traffic center on west down 580 coming out of the a

to make matters worse on the same day onyx pharmaceuticals stock is good.hey got the thumbs-up from the fda panel for the new multiple myeloma drug. the same disease treated by revlimid. it called the viability of revlimid into question to have the competitor. we have had a week to process it and we have to ask is celgene a broken company meaning the business is worse than we thought and could a long time to recover, if at all. or is it merely a broken stock connected to an intact company? i have to tell you, this is the classic example of a broken stock. i believe the underlying business, while not as good as it was a week ago, is not that bad. it may actually be just fine over the next 18 months. the selling, therefore, is overdone. the stock is way too hated and that creates an opportunity for you to buy this excellent company people have put in here. you're buying it cheaply but only buy half now. every dimwit and his brother are selling it to show their clients they weren't fooled when people see the holdings at the end of the quarter. then after, buy

shares of onyx pharmaceutical jumped 43% during today's trading, closing at $63.78. the stock surge follows a u.s. advisory panel's decision yesterday to recommend the drug for fda approval. in a recent staff report, fda officials cited five deaths related to the drug and the 22% reduction in tumors from multiple myeloma. the agency will decide the fate of the drug by may. >>> an apple away keeps the doctor away. a study in mice showed that the acid found in the peels may enhance calorie burning and prevent obesity. the acid reduces obesity by burning calories. the mice also maintained normal blood sugar levels. >> for one day, let's not worry about the apples. >> we go from that to this. >> we go to the alameda county fair where it is corn dog time. >> reporter: oh, it is corn dog time. you know, i'm going to save that corn dog, and we're going to taste some of it live here on the air. it may be cold outside, but that forecast, it's trying to heat up. we'll let you know how hot it's going to get coming up out here at the alameda county fair, celebrating 100 years, i

joining us now from the conference is tony coal, ceo of onyx pharma suit cals. joining us. >> thanks for having us. since the last time we talked at the conference, we have made a lot of progress. we are working hard to add two new therapies to our pipeline. we have great data here at asco for those deadly blood cancers. causing the disease to disappear in 80% of newly diagnosed patient. in a second therapy, hard what t.o. say, but a partner we share with bear pharmaceuticals. that presentation is coming up shortly and we are excited about both sets of data. >> that's just terrific. p. i know investors and consumers, all of us in the world are hoping for that success in terms of these cancer drugs. let me get your take on where we are in the fight against cancer right now. look at innovation. look at biotech. look at technology and tell me what has been enabled in the last couple of years and where you believe the game-changes are. >> well, i can tell you that since president nixon first started the war on cancer in the late '60s we have made incredible progress

i have looked at onyx. 33% move yesterday. once again very volatile stock.smart analysts, they only have a 20% ethicacy rate. if you made a 33% pop in two days, considering taking some off the table. >> do you have anything else? >> it's always a question. do you get in on the trade or just say i'm going to pass? i don't want to be so risky. >> all right. thank you. >> when you look at biotechs, we are looking at supreme court justice hearing all of health care affected. you might have a sell the news type event next week but biotechs are a whole different 50i8 island. >> big week with the supreme court decision coming down as early as monday. let's get to twicker. >> the way i would play this is still that levered name. you look at xco is the way i would still play nat gas or play the actual commodity. this is one you have to be in for long haul. we heard about nat gas prices going to correct and back to $5 for how long now? it feels like forever. so if you want to be long range trade, we're at the top end of the range. if you want to play a levered name, c

the army is not quite there yet, but it has been onyx -- steady improvement for several months. >> good. the police force was what i was going to ask about next. can you explain, when you say that there is an issue with mean? what you >> there is a shortage. we're about 17,000 short in the army and 11,000 short and the police. >> 17,000. how many do we have? >> that is a good question. i will ask my colleagues. >> we are short of some #? >> yes. i do not know it off the top of my head. two real issues. one is cultural. they have not been an army with professional noncommissioned armies -- noncommissioned officers before. we're trying to train the senior leadership to value noncommissioned officers. that is the barack thing going on. next is filling in their ranks. they have standards, they have to be able to read -- that is one shortfall we are working on. if these guys to recognize in the ranks, they are -- if they are a high-profile soldier, they course and to ean nco pass that. it is a work in progress, filling the slots. >> i've heard that issue in years past. i was in afghanistan t